Liang-Chuan S Wang Selected Research

vadimezan

11/2011	Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation.
9/2011	Pharmacologic activation of the innate immune system to prevent respiratory viral infections.
9/2010	Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action.
4/2010	Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).
8/2009	Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404).
1/2006	Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors.
5/2004	Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
3/2004	Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Liang-Chuan S Wang Research Topics

Disease

20	Neoplasms (Cancer) 01/2022 - 05/2004
4	Mesothelioma 06/2013 - 01/2010
3	Necrosis 08/2007 - 03/2004
2	Carcinogenesis 01/2016 - 02/2011
2	Vesicular Stomatitis 09/2011 - 01/2010
2	Infections 09/2011 - 01/2010
2	Malignant Mesothelioma 07/2011 - 01/2010
1	Carcinoma (Carcinomatosis) 07/2015
1	Human Influenza (Influenza) 09/2011
1	Pneumonia (Pneumonitis) 09/2011
1	Virus Diseases (Viral Diseases) 09/2011
1	Lung Neoplasms (Lung Cancer) 02/2011
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2010
1	Multiple Myeloma 05/2004

Drug/Important Bio-Agent (IBA)

8	vadimezanIBA 11/2011 - 03/2004
6	Proteins (Proteins, Gene)FDA Link 01/2018 - 01/2010
6	CytokinesIBA 06/2013 - 03/2004
4	Chimeric Antigen ReceptorsIBA 01/2018 - 11/2013
4	ChemokinesIBA 01/2018 - 08/2009
3	LigandsIBA 01/2022 - 04/2010
3	AntigensIBA 01/2018 - 01/2010
3	MesothelinIBA 06/2013 - 01/2010
2	AntibodiesIBA 01/2022 - 01/2010
2	Chemokine ReceptorsIBA 01/2018 - 07/2011
2	Cancer VaccinesIBA 01/2018 - 01/2010
2	Phosphotransferases (Kinase)IBA 11/2013 - 04/2010
2	Neoplasm Antigens (Tumor Antigens)IBA 06/2013 - 07/2011
2	VaccinesIBA 04/2012 - 01/2010
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 07/2011 - 02/2011
2	Messenger RNA (mRNA)IBA 04/2010 - 01/2010
2	NF-kappa B (NF-kB)IBA 04/2010 - 08/2007
1	Programmed Cell Death 1 ReceptorIBA 01/2022
1	Histones (Histone)IBA 05/2016
1	Protein Isoforms (Isoforms)IBA 05/2016
1	CXC ChemokinesIBA 01/2016
1	Interleukin-17 (Interleukin 17)IBA 01/2016
1	Extracellular Matrix ProteinsIBA 07/2015
1	GlycosaminoglycansIBA 07/2015
1	DiglyceridesIBA 11/2013
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 09/2013
1	AcidsIBA 09/2011
1	Interferon Regulatory Factor-3 (Interferon Regulatory Factor 3)IBA 09/2011
1	Therapeutic UsesIBA 07/2011
1	CCR2 ReceptorsIBA 07/2011
1	Neutralizing AntibodiesIBA 02/2011
1	xanthoneIBA 04/2010
1	Biological ProductsIBA 04/2010
1	NLR ProteinsIBA 04/2010
1	Small Interfering RNA (siRNA)IBA 04/2010
1	Chemokine CXCL10IBA 04/2010
1	Interferon-betaIBA 01/2010
1	Monoclonal AntibodiesIBA 01/2010
1	Double-Stranded RNA (RNA, Double Stranded)IBA 01/2010
1	Interferon alpha-beta Receptor (Receptor, Interferon alpha beta)IBA 01/2010
1	Monocyte Chemoattractant ProteinsIBA 01/2010
1	eIF-2 Kinase (eIF 2 Kinase)IBA 01/2010
1	InterferonsIBA 01/2010
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2007
1	Thalidomide (Thalomid)FDA Link 05/2004
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2004
1	Interferon-gamma (Interferon, gamma)IBA 03/2004

Therapy/Procedure

4	Immunotherapy 01/2018 - 01/2010
3	Therapeutics 05/2016 - 07/2011
1	Injections 01/2018
1	Intravenous Injections 07/2011
1	Oncolytic Virotherapy 01/2010